
|Videos|December 8, 2022
Online tool demonstrates potential for prostate cancer medication cost savings
Author(s)Urology Times staff
“It's a really simple tool to predict your out-of-pocket costs,” says Benjamin Pockros, MD, MBA, of Medicare Plan Finder.
Advertisement
In this interview, Benjamin Pockros, MD, MBA, discusses the presentation “Out-Of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Part D Plan: An Online Tool Could Save Patients Thousands of Dollars,” which he gave at the 2022 Society of Urologic Oncology Annual Meeting in San Diego, California. Pockros is a urology resident at the University of Michigan, Ann Arbor.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5













